Dimitri Gitas Appointed Country President of Novartis Pharmaceuticals Canada
Table of Contents
Montreal, Canada – Novartis Pharmaceuticals Canada Inc. (Novartis Canada) has announced the appointment of Dimitri Gitas as its new Country President, effective december 1, 2025. A Canadian native, Gitas brings extensive experience in the life sciences and healthcare industries, with a proven track record of leadership across multiple international markets. https://www.novartis.ca/news/media-releases/novartis-canada-appoints-dimitri-gitas-country-president
Gitas succeeds Mark Vineis,who has transitioned to a new role within Novartis.
Leadership Background and Experience
Prior to joining Novartis Canada, Gitas served as Managing Director for MSD (known as Merck & Co., Inc. in the United States and Canada). His career spans leadership positions in Canada, the United States, Greece, Poland, and Switzerland, demonstrating a broad understanding of the global pharmaceutical landscape.
Strategic Focus for Novartis Canada
As Country President, Gitas will be responsible for leading the company’s overall strategy and operations in Canada. A key focus will be on developing healthcare solutions for patients in four core therapeutic areas:
* Oncology: Cancer treatment and research.
* Immunology: Treatments for immune-related diseases.
* Neuroscience: Addressing neurological disorders.
* Cardiovascular, Renal & Metabolic Diseases: Treatments for heart, kidney, and metabolic conditions.
Gitas’ Vision for the Future
“Novartis has never backed down from some of the toughest challenges in medicine. I’m energized to join a company whose legacy is built on such bold innovation,” said Gitas in a press release. He also expressed his excitement about returning to Canada and collaborating with stakeholders to strengthen the life sciences sector, stating, “Together, we’ll drive innovation and ensure Canadian patients have timely access to the medicines they need.”
Novartis in Canada
novartis is a global healthcare company based in Basel, Switzerland. Novartis Canada is committed to reimagining medicine to improve and extend people’s lives. The company invests heavily in research and development, focusing on innovative therapies to address unmet medical needs. https://www.novartis.com/about-us/country-presence/canada
Key takeaways:
* Dimitri Gitas has been appointed Country President of Novartis Canada, effective December 1, 2025.
* He brings extensive international experience in the pharmaceutical industry, most recently from MSD.
* Gitas will focus on driving innovation and improving patient access to medicines in key therapeutic areas.
* He succeeds Mark Vineis, who has taken on a new role within novartis.
Related reading